ASCEND-Gastric is a prospective, multi-omics, observational study aimed at detecting gastric cancer by combined assays for serum protein markers, deep sequencing of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA) mutation and circulating RNA. The study will enroll 498 participants, including 128 patients with benign gastric diseases and 370 patients with gastric cancer.
Study Type
OBSERVATIONAL
Enrollment
498
blood-based biomarkers analyses
ZhongShan hospital FuDan university
Shanghai, Shanghai Municipality, China
RECRUITINGSensitivity and specificity of the cfDNA methylation-based model in detecting gastric cancer.
Time frame: 30 months
The differences of sensitivity and specificity in gastric cancer participants at different clinical stages.
Time frame: 30 months
Sensitivity and specificity for detecting gastric cancer of a cfDNA methylation-based model, in combination with other biomarkers.
Time frame: 30 months
Sensitivity and specificity of a ctDNA mutation-based model and a serum protein-based model in detecting gastric cancer, respectively.
Time frame: 30 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.